Skip to main content
Fig. 6 | BMC Pulmonary Medicine

Fig. 6

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Fig. 6

Association of ANK2 expression with clinical features and survival of LUAD patients A: Pathological stage. B: Histological grade. C: SWI-SNF complex alteration. D: P53/Rb-related pathway alteration. E: MYC/MYCN alteration. F: WNT pathway alteration. G: HIPPO pathway alteration. H: Kaplan–Meier curves for OS of patients in the high- and low-ANK2 expression LUAD. I: Kaplan–Meier curves for DSS of patients in the high- and low-ANK2 expression LUAD. J: Meta-analysis was performed to integrate HR values about ANK2 expression and OS from ten GEO LUAD cohorts. K: Diagnostic ROC curve analysis of ANK2 in LUAD (*P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us